CTLA4 and malignant colon neoplasm: Larimer et al. evaluated 89Zr-DFO-CD3, a radiolabeled anti-CD3 radiopharmaceutical in mice bearing CT26 tumors, an immunocompetent colon cancer model, that had been treated with anti-CTLA-4.